Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
40 Leser
Artikel bewerten:
(0)

INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences

SANTA MONICA, Calif., March 7, 2013 /PRNewswire/ --INVENT Ventures, Inc. (OTC QB: IDEA), a seed-stage venture fund and technology incubator, today announced that it has led the seed financing round in Sanguine BioSciences, a biotechnology company empowering patients in biomedical research. Along with INVENT, Heliant Ventures, a VC technology fund, jointly lead the round of investment in Sanguine.

INVENT's investment in Sanguine keeps with its strategy of building and investing in evolving and rapidly growing companies. In addition to Sanguine BioSciences, which supplies DNA data and bio-specimen to research organizations for the development of personalized medicines, INVENT has also developed Virurl Inc., one of the early pioneers in native advertising. Virurl builds tools and technologies to create native advertising campaigns, and has raised $1.2M in seed financing to date. Since formation in 2010, INVENT has built six technology companies, which have raised over $3.5M at an aggregate valuation over $10M, with under $450K of capital investment.

"We are thrilled to invest in Sanguine alongside Heliant Ventures and to further reinforce our holdings in what we believe are the next generation of exciting young technology companies," said Bryce Knight, CEO of INVENT. "With Sanguine, Virurl and our other portfolio companies, we have strong positions in technology businesses that are readily scalable, and we believe that each has the potential to go public if they elect to. Considering the vast value creation ability of technology companies, private and public investors alike are looking for exposure to early-stage technology, and we are very excited to be in a position to fulfill this need."

About INVENT Ventures, Inc.
INVENT Ventures Inc. (IDEA) is a publicly traded venture fund that builds and invests in transformative technology businesses. INVENT pursues ventures in the consumer Internet, mobile and biotechnology markets, and has built six companies at various stages of development. INVENT is headquartered in Santa Monica, California in the renowned Silicon Beach area. For more information on INVENT, visitwww.invent.vc.

Forwarding-Looking Statements
Cautionary Language Regarding Forward Looking Statements: This release and any attachments contain forward-looking statements within the meaning of the "safe harbor" provisions of the Federal securities laws, including Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties. Words such as "will," "believe," "intend," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include the quotations from management in this press release, as well as any statements regarding the Company's anticipated financial results and strategic and operational plans. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may contribute to such differences include, but are not limited to: the Company's ability to deliver an adequate rate of growth and manage such growth; the impact of changes in government regulation and industry standards; the Company's ability to maintain and increase the number of visitors to its websites; the Company's ability to identify and manage acquisitions; the impact of the current economic climate on the Company's business; the Company's ability to attract and retain qualified executives and employees; the Company's ability to compete effectively against others in the online marketing and media industry; the impact and costs of any failure by the Company to comply with government regulations and industry standards; and costs associated with defending intellectual property infringement and other claims. More information about potential factors that could affect the Company's business and financial results is contained in the Company's latest annual report. These forward looking statements are made as of today's date and, except as otherwise required by law, the Company does not intend and undertakes no duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.

SOURCE INVENT Ventures, Inc.

© 2013 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.